Open Access Journal

ISSN : 2456-1304 (Online)

International Journal of Engineering Research in Electronics and Communication Engineering(IJERECE)

Monthly Journal for Electronics and Communication Engineering

Open Access Journal

International Journal of Science Engineering and Management (IJSEM)

Monthly Journal for Science Engineering and Management
Call For Paper : Vol 11, Issue 05, May 2024

ISSN : 2456-1304 (Online)

Call for Paper

Vol 11, Issue 05, May 2024

Indexing

Molecular Docking Study of Some Phytosterols of Luffa echinata Fruits as a Anti-Asthmatic Activity

Author : Denish Prajapati 1 Pinesh Patel 2

PDF

Date of Publication :1st October 2022

Abstract: The climbing plant Luffa echinata ROXB. (Curcurbitaceae) has been used traditionally to treat a number of diseases. Luffa echinata ROXB. Fruit has been shown in scientific studies to have antioxidant, antidepressant, anxiolytic, antiepileptic, hepatoprotective, anti-cancer, and asthmatic properties. However, there has been little research of asthmatic activity. Using AutoDock 4.2, we investigated the Luffa echinata ROXB. as a anti-asthmatic effect in this study. IL-13 is a powerful stimulator of all interleukins implicated in the inflammatory process connected to asthma. Due to this, phytosterols and its analogue were docked with IL-13 (PDB: 3L5X), and their binding complementarities were assessed in this study. It was found that phytosterols are well accommodated in IL-13's active site. Although the study's limited patient population, asthma can raise the incidence of COVID-19 hospitalisation in people 18 to 49 years old. Therefore, future research is necessary to investigate the ability of Luffa echinata ROXB. against COVID-19.

Reference :

    1. Frieri M. “Asthma concepts in the new millennium: update in asthma pathophysiology”, In Allergy and asthma proceeding: OceanSide; 2005. pp. 83- 88.
    2. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. “Safety of inhaled corticosteroids” Proceedings of the American ThoracicSociety.2004;1(3): 1715
    3. Lama VN, Murray S, Mumford JA, Flaherty KR, Chang A, Toews GB, Peters- Golden M, Martinez FJ, “Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients”, American Journal of Respiratory and Critical Care Medicine. 2005; 172(3):379-83.
    4.  Mukherjee PK, “Quality control of herbal drugs: an approach or evaluation of botanicals”, New Delhi: Business Horizons Publication. 2002.
    5. Harsh mohan; Text book of pathology; jaypee brothers medical publishers New Delhi; 2005.pp 491 – 492. Kaufman G. Asthma: pathophysiology, diagnosis and management. Nurs Stand. 2011;26(5):48. doi:10.7748/ns.26.5.48.s55.
    6. Pedersen SE, Hurd SS, Lemanske RF Jr, et al. Global strategy for the diagnosis and management of asthma in children 5 years and younger. Pediatr Pulmonol. 2011;46(1):1–17. doi:10.1002/ppul.21321.
    7. Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. Emerg Med J. 2007;24(12):823–830. doi:10.1136/emj.2007.052050.
    8. Adams BK, Cydulka RK. Asthma evaluation and management. Emerg Med Clin N Am. 2003;21(2):315–330. doi:10.1016/S0733-8627(03)00015-4.
    9. Barnes PJ. Drugs for asthma. Br J Pharmacol. 2006;147(S1):S297–S303. doi:10.1038/sj.bjp.0706437. [11] DiMartino SJ. Idiopathic inflammatory myopathy: treatment options. Curr Rheumatol Rep. 2008;10(4):321. doi:10.1007/s11926-008-0051-4.
    10. Amaral-Machado L, Oliveira WN, Moreira-Oliveira SS, et al. Use of natural products in asthma treatment. Evid. Based Complementary Altern. Med. 2020;2020:1–35. doi:10.1155/2020/1021258.
    11. Patel Ramesh, Jawaid Talha, Gautam Piyush and Dwivedi, “Herbal remedies for Gestroprotective Action: A Review.” Int. J. of Phaytopharm. 2012, 2, 30-38.
    12. Kumar RK, Herbert C, Foster P. The “Classical” ovalbumin challenge model of asthma in mice. Curr. Drug Targets. 2008;9(6):485–494. doi:10.2174/138945008784533561.
    13. Khodoun MV, Orekhova T, Potter C, et al. Basophils initiate IL-4 production during a memory T-dependent response. J Exp Med. 2004;200(7):857–870. doi:10.1084/jem.20040598.
    14. Liu L, Rich BE, Inobe J-I, et al. Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. Int Immunol. 1998;10(8):1017–1026. doi:10.1093/ intimm/10.8.1017.
    15. [17] Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21 (1):425–456. doi:10.1146/annurev.immunol.21.120601.141142.
    16. Elias JA, Lee CG, Zheng T, et al. Interleukin-13 and leukotrienes: an intersection of pathogenetic schema. Am J Respir Cell Mol Biol. 2003;28(4):401–404. doi:10.1165/rcmb.F264.
    17. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004;202(1):175–190. doi:10.1111/j.0105-2896.2004.00215.x.
    18. Giri s, Lokesh CR, Sahu S, Gupta N, “Luffa echinata: Healer plant or potential killer”, asian journal of postgraduate medicine, volume 60, issue (1),jan and march-2014,72-74.
    19. Deepak Kailasiya, S.K..Jain,Shashi Alok, “Phytochemical screening on the aerial part of the luffa echinata Lin.”, International Jounal of pharmaceutical sciences and research, 2011, vol 2(9), 2446-2450.
    20. Indian Medicinal Plants Vol. : 3, Kirtikar K. R. & Basu B. D., Dehradun, India : International Book Distributor 2005, Page No. : 1125-1126.

Recent Article